HOWL

Werewolf Therapeutics, Inc.

7 filings tracked

healthcarebiotechnologySMALL ($300M-2B)

Signal Magnitude Chart

bullish

bearish

neutral

Signal Timeline

bullishMay 7

Reduced operating expenses by $4.7M through a 64% workforce reduction.

margin expansion

60%

bullishMay 7

Eliminated high-interest K2HV term loan and derivative liability.

debt restructure

70%

bullishMay 7

Monetized 898 program via $21M sale to Jazz Pharmaceuticals.

divestiture

50%

bearishMay 7

Severe liquidity constraints and 'going concern' doubt with limited ATM capacity.

capital raise

80%

bullishMay 7

Reduced operating expenses by $4.7M through a 64% workforce reduction.

margin expansion

60%

bullishMay 7

Eliminated high-interest K2HV term loan and derivative liability.

debt restructure

70%

bullishMay 7

Monetized 898 program via $21M sale to Jazz Pharmaceuticals.

divestiture

50%

bearishMay 7

Severe liquidity constraints and 'going concern' doubt with limited ATM capacity.

capital raise

80%

bullishMay 7

Reduced operating expenses by $4.7M through a 64% workforce reduction.

margin expansion

60%

bullishMay 7

Eliminated high-interest K2HV term loan and derivative liability.

debt restructure

70%

bullishMay 7

Monetized 898 program via $21M sale to Jazz Pharmaceuticals.

divestiture

50%

bearishMay 7

Severe liquidity constraints and 'going concern' doubt with limited ATM capacity.

capital raise

80%

bullishMay 7

Reduced operating expenses by $4.7M through a 64% workforce reduction.

margin expansion

60%

bullishMay 7

Eliminated high-interest K2HV term loan and derivative liability.

debt restructure

70%

bullishMay 7

Monetized 898 program via $21M sale to Jazz Pharmaceuticals.

divestiture

50%

bearishMay 7

Severe liquidity constraints and 'going concern' doubt with limited ATM capacity.

capital raise

80%

bullishMay 7

Reduced operating expenses by $4.7M through a 64% workforce reduction.

margin expansion

60%

bullishMay 7

Eliminated high-interest K2HV term loan and derivative liability.

debt restructure

70%

bullishMay 7

Monetized 898 program via $21M sale to Jazz Pharmaceuticals.

divestiture

50%

bearishMay 7

Severe liquidity constraints and 'going concern' doubt with limited ATM capacity.

capital raise

80%

bullishMay 7

Reduced operating expenses by $4.7M through a 64% workforce reduction.

margin expansion

60%

bullishMay 7

Eliminated high-interest K2HV term loan and derivative liability.

debt restructure

70%

bullishMay 7

Monetized 898 program via $21M sale to Jazz Pharmaceuticals.

divestiture

50%

bearishMay 7

Severe liquidity constraints and 'going concern' doubt with limited ATM capacity.

capital raise

80%

neutralMar 27

Executed a 64% workforce reduction as part of a strategic restructuring plan.

management change

70%

bearishMar 27

Reported an annual operating loss of $60.8 million with substantial doubt about going concern.

margin compression

90%

bullishMar 27

FDA provided initial guidance for a monotherapy registration path for WTX-124 in melanoma.

regulatory action

80%

Filing History

10-QMay 7, 2026

The 10-Q filing reveals a company in a race against time, attempting to optimize its cost structure and balance sheet before its cash reserves vanish. The successful sale of the 898 program and the elimination of the K2HV loan are positive steps toward cleaning up the capital structure, but they do not solve the fundamental lack of revenue and the high cost of ongoing clinical trials. Investors are now faced with a binary outcome: either the company secures a high-value partnership or acquisition based on the PREDATOR platform's potential, or it collapses under the weight of its own burn rate. The upcoming Q3 2026 data readouts for WTX-124 and WTX-330 represent the final catalysts that will likely determine if the company is a viable acquisition target or a candidate for liquidation.

10-KMar 27, 2026

The 10-K paints a picture of a company in a race against time. On one side, the PREDATOR platform is showing genuine promise in solving the toxicity issues of cytokine therapy, potentially unlocking a massive market for safer immunotherapies. On the other, the financial reality is stark: Werewolf is a pre-revenue entity with a looming cash cliff and a fragile operational structure. Investors are essentially trading a high-quality scientific asset trapped within a distressed financial shell. The outcome hinges on whether the strategic review can secure a partnership or acquisition before the cash expires in late 2026. The convergence of the Q2 2026 clinical readouts and the August 2026 leadership milestones will determine if Werewolf is a breakthrough success or another cautionary tale of biotech volatility.